Remove Affiliate Remove Distribution Remove Finance Remove New Zealand
article thumbnail

Invest in Israel Newsletter August 2010 Edition

VC Cafe

Medical product giant Baxter International and Israeli biopharmaceutical company Kamada entered into a definitive distribution agreement for Glassia, the first and only liquid, ready-to-use Alpha1-Proteinase inhibitor that treats genetic lung-damaging disorder alpha-1 antitryspin (AAT). Canada, Australia and New Zealand.